ArticleThe Journal of clinical investigation2009
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients.
Article in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 75 citations in OpenAlex.
- A Comprehensive Pan-Cancer Analysis of Cytochrome C Oxidase Assembly Factor 1 (COA1) Reveals Instrumental Role of Mitochondrial Protein Assembly in Cancer that Modulates Disease Progression and Prognostic Outcome.Cell biochemistry and biophysics · 2024Article
- Inhibition of Heme Oxygenase 1 Suppresses Growth, Migration, and Invasion, and Regulates Tumor-Infiltrating CD8+ T Cells and in Uveal Melanoma.Investigative ophthalmology & visual science · 2024Article
- Relationship Between PD-L1, PD-1, CD8 and Clinicopathological Factors in Primary SCCs.Dermatology practical & conceptual · 2024Article
- Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity.Cancers · 2022Review
- The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.Cancer management and research · 2022Review
- Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma.PloS one · 2022Article
- Article
- Heme Oxygenase-1 Signaling and Redox Homeostasis in Physiopathological Conditions.Biomolecules · 2021Review
- The New Old CD8+ T Cells in the Immune Paradox of Pregnancy.Frontiers in immunology · 2021Review
- Immunomodulatory Effects of Heme Oxygenase-1 in Kidney Disease.Frontiers in medicine · 2021Review
- Immune Modulation by Inhibitors of the HO System.International journal of molecular sciences · 2020Review
- Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.Frontiers in immunology · 2020Article
- Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients.Cancer biology & medicine · 2019Article
- Heme oxygenase inhibition in cancers: possible tools and targets.Contemporary oncology (Poznan, Poland) · 2018Review
- Anti-regulatory T cells.Seminars in immunopathology · 2017Review
- PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.Oncoimmunology · 2016Article
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Journal of the National Cancer Institute · 2015Article
- Heme oxygenase-1: for better, for worse, in sickness and in health.Oncotarget · 2015Article
- Progesterone and HMOX-1 promote fetal growth by CD8+ T cell modulation.The Journal of clinical investigation · 2015Article
- Heme oxygenase-1: emerging target of cancer therapy.Journal of biomedical science · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treg deficiencies are associated with autoimmunity. Conversely, CD4+ and CD8+ Tregs accumulate in the tumor microenvironment and are associated with prevention of antitumor immunity and anticancer immunotherapy. Recently, CD4+ Tregs have been much studied, but little is known about CD8+ Tregs and the antigens they recognize. Here, we describe what we believe to be the first natural target for CD8+ Tregs. Naturally occurring HLA-A2-restricted CD8+ T cells specific for the antiinflammatory molecule heme oxygenase-1 (HO-1) were able to suppress cellular immune responses with outstanding efficacy. HO-1-specific CD8+ T cells were detected ex vivo and in situ among T cells from cancer patients. HO-1-specific T cells isolated from the peripheral blood of cancer patients inhibited cytokine release, proliferation, and cytotoxicity of other immune cells. Notably, the inhibitory effect of HO-1-specific T cells was far more pronounced than that of conventional CD4+CD25+CD127- Tregs. The inhibitory activity of HO-1-specific T cells seemed at least partly to be mediated by soluble factors. Our data link the cellular stress response to the regulation of adaptive immunity, expand the role of HO-1 in T cell-mediated immunoregulation, and establish a role for peptide-specific CD8+ T cells in regulating cellular immune responses. Identification of potent antigen-specific CD8+ Tregs may open new avenues for therapeutic interventions in both autoimmune diseases and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.